Breaking News

Supernus Acquires US WorldMeds’ CNS Portfolio

Adds three marketed products in the U.S. and a product candidate in late-stage development.

By: Contract Pharma

Contract Pharma Staff

Supernus Pharmaceuticals, Inc. has entered into a definitive agreement to acquire US WorldMeds’ CNS portfolio, adding three marketed products in the U.S. and a product candidate in late-stage development. Products include APOKYN (apomorphine hydrochloride) injection for Parkinson’s disease (PD); MYOBLOC (rimabotulinumtoxinB) injection for the treatment of pain associated with cervical dystonia; XADAGO (safinamide) tablets indicated as an adjunctive treatment for PD episodes; and Apomorphine I...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters